Secukinumab

Uses

Dosage & preparation

Risks & contraindications

Highlighted claims

• Treatment-as-usual receives standard secukinumab dosing in the trial. — Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial
• The experimental arms receive reduced secukinumab exposure combined with the conditioned beverage. — Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial
• The continuous reinforcement arm uses full-dose acquisition followed by continuous 75 mg secukinumab on the same visit schedule. — Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial
• The partial reinforcement arm uses full-dose acquisition followed by alternating 150 mg secukinumab or placebo on later visits. — Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial
• Patients with contraindications to secukinumab or prior secukinumab treatment are excluded. — Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial
• Participants can access standard secukinumab treatment or another therapy after the study. — Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial